

OSPREY

AMD

OSPREY C-12-006 HAWK C001

OSPREY C-12-006^{2,3}

20200010
3 Dugel PU, et al. Ophthalmology 2017;124(9):1296-1304
DOI:10.1016/j.ophtha.2017.03.033

12mg/50µL, 6mg/50µL, 2mg/50µL

50% choroidal neovascularization (CNV) 89%

※1

- CNV 50%
- intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (sub-RPE) fluid
- ETDRS (early treatment diabetic retinopathy study) 73/23

OSPREY C-12-006
6mg/0.05mL
4
3
12
1
8
7.1
7.2
17.1.1
17.1.2

OSPREY C-12-006

Source URL: https://prod.pro.novartis.com/jp-ja/products/beovu/amd/clinical_07